Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study
ConclusionThese findings provide real-world evidence that evolocumab use is in accordance with its international guideline-recommended place in dyslipidemia therapy, as well as confirmation of its effectiveness and safety in a heterogeneous population. Evolocumab can address a healthcare gap in the management of dyslipidemia by increasing the proportion of patients achieving LDL-C goals recommended to lower cardiovascular risk.Graphical Abstract
Source: Cardiology and Therapy - Category: Cardiology Source Type: research
More News: Canada Health | Cardiology | Cardiovascular | Cholesterol | Colombia Health | Heart | Kuwait Health | Mexico Health | Middle East Health | Saudi Arabia Health | Statin Therapy | Study